



Towards utilization of the human genome and microbiome for personalized nutrition

Stavros Bashiardes^{1,4}, Anastasia Godneva^{2,3,4},
Eran Elinav^{1,5} and Eran Segal^{2,3,5}

Generalized dietary and lifestyle guidelines have been formulated and published for decades now from a variety of relevant agencies in an attempt to guide people towards healthy choices. As the pandemic rise in metabolic diseases continues to increase, it has become clear that the one-fit-for-all diet approach does not work and that there is a significant variation in inter-individual responses to diet and lifestyle interventions. Recent technological advances have given an unprecedented insight into the sources of this variation, pointing towards our genome and microbiome as potentially and previously under-explored culprits contributing to individually unique dietary responses. Variations in our genome influence the bioavailability and metabolism of nutrients between individuals, while inter-individual compositional variation of commensal gut microbiota leads to different microbe functional potential, metabolite production and metabolism modulation. Quantifying and incorporating these factors into a comprehensive personalized nutrition approach may enable practitioners to rationally incorporate individual nutritional recommendations in combating the metabolic syndrome pandemic.

Addresses

¹ Immunology Department, Weizmann Institute of Science, 76100 Rehovot, Israel

² Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, 76100 Rehovot, Israel

³ Department of Molecular Cell Biology, Weizmann Institute of Science, 76100 Rehovot, Israel

Corresponding authors: Elinav, Eran (eran.elinav@weizmann.ac.il), Segal, Eran (eran.segal@weizmann.ac.il)

⁴ These first authors contributed equally.

⁵ These last authors contributed equally.

Current Opinion in Biotechnology 2018, 51:57–63

This review comes from a themed issue on **Systems biology**

Edited by **Nathan Price** and **Eran Segal**

<https://doi.org/10.1016/j.copbio.2017.11.013>

0958-1669/© 2017 Published by Elsevier Ltd.

Introduction

The past century has witnessed our modern ‘developed’ societies adopting dramatic changes in lifestyle and

dietary habits that are characterized by limited physical activity in conjunction with over nutrition with foods high in fat, processed meat, sugars, salt and refined grains while being low in fruits and vegetables [1]. In parallel, the same societies have developed a global pandemic consisting of obesity, type 2 diabetes [2], non-alcoholic fatty liver disease and their many complications, collectively accounting for the morbidity and mortality of billions of individuals worldwide. In parallel, concerted efforts have focused on determining the components constituting a healthy and beneficial diet, and on educating the public on healthy dietary practices along generalized lines. Of note is that the US government has been publishing dietary guidelines and advice for over a century, with no less than 900 publications (guidance and educational) during that time (U.S. Department of Agriculture; URL: <http://fnic.nal.usda.gov/dietary-guidance/myplate-and-historical-food-pyramid-resources>). Easy to comprehend tools such as the Food Guide Pyramid and more recent MyPlate act as beacons of daily nutritional recommendation.

Despite the enormous implications of the metabolic syndrome pandemic on economy and health and widespread efforts to understand its causes and to develop effective interventions, it has not been efficiently controlled to date [2]. One possible cause of this failure relates to our poor understanding of nutritional causes contributing to the prevalence of obesity, diabetes, NAFLD and their common complications. Commonly, in the last three decades nutritional guidelines have attempted to address the epidemic by prescribing population-wide recommendations for ‘healthy’ versus ‘unhealthy’ foods [3]. These often failed, as seen by the global increase in the prevalence of obesity, a major risk factor of metabolic disease, with over 300 million adults worldwide estimated to be suffering of morbid obesity [4]. Furthermore, there has been a significant rise in the number of individuals with diabetes worldwide, from 108 million adults in 1980 to 422 million in 2014 [5]. This astounding rise in the prevalence of closely associated diseases constituting the ‘metabolic syndrome’ carries significant global medical and economic consequences [6].

The disappointing efficacy of dietary interventions to obesity and its complications may stem from lack of regard to inter-individual variabilities in dietary responses [7]. Indeed, a recent realization is that some of the

metabolic responses to diet differ from one individual to another, as exemplified by cholesterol metabolism and postprandial hyperglycemia, risk factors for cardiovascular disease (CVD) and type 2 diabetes [8,9], and by recent studies demonstrating that not all individuals respond in the same way to changes in lifestyle and this certainly applies to dietary changes [10,11]. Fundamental factors suggested to determine our individualized response to foods, and the biological implications of their consumption include the human genome [12], our epigenome [13], our microbiome [14**], and inter-personal variations in a variety of environmental exposures and life style factors [15]. Recent technological advances have given us an unprecedented insight into this interpersonal variability, in terms of the ability to accurately quantify genetic background and microbiome community structure, both of which modulate metabolic activity and form complex and poorly understood interactions with the components of our diet, modulating their metabolism and utilization. The genetic contribution towards disease risk has been known and studied for decades, while the commensal microbiota contribution has been ignored until recently and is being increasingly appreciated to contribute to individualized responses to food, and even link a variety of environmental factors to host physiology [16]. The inclusion of the microbiome as a necessary element explaining personal uniqueness has led to a paradigm shift in terms of our understanding of inter-individual variability and how it influences responses to environmental factors (such as diet). We are now in an era where we finally have the technologies that allow us to devise data-driven approaches to personalized diet interventions that take into account variation at the level of our genome and microbiome.

In this mini-review we discuss the current state of play with regards to personalized nutrition and highlight the main factors modulating individual responses to nutritional interventions.

Source of human variation modulating responses to diet

The main sources of human variation that modulate responses to diet include the genome and microbiome. While both may be used for a person-specific diagnosis and stratification of dietary responses and recommendations, the microbiome is also amenable to modulation by approaches such as pro-biotics, pre-biotics, antibiotic treatment, and recently post-biotic intervention, thereby representing an exciting new potential for preventive and interventional modification of personalized dietary responses.

Human genome

Successful full genome characterization by the Human Genome project [17] was followed by additional large collaborative efforts to characterize human genetic


variation, including the International HapMap consortium [18], the Human Variome Project [19] and the 1000 Genomes Project Consortium [20]. Large scale genetic variation information has facilitated population based studies such as genome-wide association studies (GWAS) to determine genetic influences on disease risk [21]. It is now accepted that genetic variations influence the bioavailability and metabolism of nutrients between individuals but also between ethnic groups. This notion has revolutionized the field of nutritional sciences and has paved the way for personalized nutrition approaches.

Propagated by rampant advances in genomics technologies, an unprecedented volume of data on genetic variations throughout the genome has been acquired and characterized [19,20]. Epidemiological nutritional studies have suggested an association between diet and chronic diseases, revolutionizing the field of nutritional research by incorporating individual genetic information (Figure 1) and giving rise to a new area of study, namely nutrigenomics that is the study of how our genes influence dietary intake. Understanding these underlying interactions can translate into individual specific nutritional interventions based on their genetic characteristics and result in the identification of positive and negative responders or those that do not respond at all to diet interventions.

The nutrigenomics approach was best exemplified in rare monogenic disorders such as phenylketonuria (PKU). PKU patients have mutations in the *PAH* gene (encodes the enzyme that converts phenylalanine to tyrosine) resulting in an accumulation of phenylalanine and its toxic metabolites, leading to mental retardation and delayed development. Nutritional intervention (restricted in phenylalanine and supplemented in tyrosine) is currently regarded as the only available treatment, which, when properly followed, prevents the deleterious life-risking complications of PKU. Another example of nutrigenomics interventional approaches in a monogenic disease can be seen in the case of Galactosemia, a metabolic disease resulting in the inability to metabolize galactose. It represents a group of three metabolic diseases (Type I, Type II and Type III galactosemia caused by mutations in the genes *GALT*, *GALK1*, *GALE* respectively) with deficiencies in enzymes from the Leloir pathway of galactose catabolism [22]. Currently, the only form of effective treatment for galactosemia is galactose restriction.

Despite the efficiency exemplified in the above monogenic disorders in using genomics for dietary recommendations, adaptation of genomic diagnostics and stratification tools in tailoring diets for the prevention and treatment of chronic polygenic complex diseases such as cancer, CVD, obesity and type 2 diabetes has proven much more complicated and of limited value. Examples

Figure 1



Rationally designed personalized dietary approaches determine the effects of numerous parameters on diet response (e.g. microbiome composition, genome variability, personal lifestyle, medical metadata). Machine learning algorithms utilize these comprehensive data sets to deliver dietary recommendations.

of genomic contribution to dietary planning in the context of multi-factorial diseases are sparse and include enhanced benefits of Mediterranean diet in preventing breast cancer risks in patients carrying SNPs in *GST1* (glutathione S-transferase 1) and *Nat2* (N-acetyltransferase 2) of the xenobiotic metabolism pathway [23]. Another example relates to individuals with the *APOA2* CC genotype who are found to feature a greater susceptibility to increased BMI and obesity upon consumption of a diet that is abundant in high-saturated fat [24]. These individuals with the *APOA2* CC genotype may therefore benefit from following a diet regimen with reduced saturated fat intake. Furthermore, transcription factor 7-like 2 gene (*TCF7L2*) polymorphism rs7903146 (C>T) has been associated with type 2 diabetes [24]. A randomized trial following 7018 participants found Mediterranean diet to decrease fasting glucose and lipids and reduced the incidence of stroke in TT homozygote individuals [25].

However, the many other claimed nutrigenomics approaches of effectively influencing dietary choices among the general population at risk have mostly proven to be non-evidence based. For example, Pavlides *et al.* [26**] show this in a meta-analysis focusing on 38 genes that are included in commercially available nutrigenomics tests and are commonly analyzed. They found

inconsistencies and conflicting results with regards to gene–diet associations, as well as a lack of significant association for these 38 genes [26**]. Apart from indicating the need for a solid scientific basis in the implementation of nutrigenomics, it also highlights the fact that these are still early days and the field is in need of further development. Furthermore, a meta-analysis of thirteen observational studies reporting gene–macronutrient interactions and Type 2 diabetes [27**] showed that none of the eight unique interactions reported to be significant between macronutrients and genetic variants in or near *TCF7L2*, *GIPR*, *CAV2* and *PEPD* were replicated.

Furthermore, the added value of providing elaborate genetic information to individuals undergoing personalized nutrition (PN) advice should be considered. It is indicative that the largest intervention study to date comparing the effect of PN on health related dietary behavior showed the advantage of PN advice based on individual baseline diet and lifestyle over a conventional approach. However, no additional advantage was found by basing PN advice on individual baseline diet and phenotype (anthropometry and medical metadata), or individual baseline diet plus phenotype plus genotype (five diet responsive genetic variants) [28]. It should be noted however that the baseline diets, lifestyle and phenotypes were self-reported by participants,

potentially introducing a bias and in turn reducing the benefits of including genetic information.

Gut microbiome

A recently appreciated factor that greatly contributes to our understanding of inter-individual human variability is the enormous micro-organismal ecosystem and its gene pool that are integrated into all mucosal surfaces of the human body, collectively termed the microbiome. The most heavily colonized and studied ecosystem, the gut microbiome, contains a heavy population of bacteria of equal numbers as our own cells [29] and as many as 100 times more genes as the human genome, and is considered to be our 'second genome' [30]. In addition to bacteria, the gut microbiome contains a plethora of viruses [31], archaea [32], fungi [33] and parasites [34], collectively forming a large ecosystem that is increasingly recognized to impact multiple facets of human physiology [35]. Among others, our microbiome modulates our metabolism and disease risk [36]. The inter-individual microbiota community structure of healthy individuals differs significantly in colonized sites such as gut and skin [37–39]. Furthermore, inter-individual variation in gene content of microbiota species leads to differences in their functional potential [40].

Commensal microorganisms have a deeply symbiotic relationship with their human host, providing it with many essential functions [41]. It is now established that microbiota, along with other important factors such as lifestyle and genetics, can modulate responses to diet. Changes in diet can modulate host physiology and disease through commensal microbiota. For example, elevated levels of Trimethylamine-N-oxide (TMAO) and other choline metabolites are associated with greater risks of adverse cardiovascular events and are dependent on gut microbiome metabolism [42]. Plasma levels of TMAO in patients were significantly suppressed after the intake of antibiotics and reappeared after cessation of antibiotics [42]. The intra-personal difference in the circulation of TMAO when consuming TMAO precursors is a function of gut microbiome, with people who showed greater TMAO response having the higher ratio of *Firmicutes* to *Bacteroidetes* [43].

Another example is of flavonoids, polyphenolic compounds found in numerous dietary components including vegetables and fruits. Several subclasses of flavonoids have been suggested to play a role in human physiology affecting for example cardiometabolic health as well as cognitive function [44]. A large amount of ingested flavonoids reach the colon and undergo hydrolysis and fermentation by commensal microbiota. A high level of variability in flavonoid bioconversion occurs as a result of variability in microbiome composition with some individuals having a greater ability to convert flavonoids [45] that

can result in the production of metabolites with greater biological activity.

In addition to the above examples demonstrating how the microbiome responds to diet and utilizes dietary compounds in its interactions with the host, diet is also a crucial component in shaping the microbial environment [46]. Following some types of dietary interventions, the microbiome may undergo changes in less than a week, and these changes occur at both taxonomic and bacterial gene expression levels [47]. Importantly, community changes imposed by diet can be predicted, with important ramifications on the prospect of dietary interventions [48*]. It is however relevant to point out that although dramatic dietary alterations indeed impact the microbiome structure, more subtle changes may not [49], demonstrating potential microbiome resilience to some less dramatic dietary changes, as indicated by Korem *et al.* [48*]. Furthermore, changes conferred to the microbiome structure can be direct, and be mediated through diet composition, for example high protein and animal fat as opposed to carbohydrates that can each drive the abundance of particular bacteria such as *Bacteroides* and *Prevotella* respectively [50]. Changes conferred can also be indirect via microbiota-associated metabolites innate immune modulation, whereby microbiota metabolites modulate NLRP6 inflammasome signaling and the resulting microbiome-host interactions can influence community stability [51].

Towards individualized dietary approaches

Moving towards rationally designing personalized dietary approaches must take into account the intricacies of the microbiome and its effects on human physiology, as well as details on person specific life style and medical metadata. Exemplifying the use of personalized nutritional intervention to lower postprandial glycemic response, Zeevi *et al.* [14**] developed a machine-learning algorithm integrating numerous clinical blood parameters and gut microbiota data to accurately predict postprandial blood glucose responses to meals on a personal level. Diet intervention based on these predictions proved to be successful in lowering postprandial responses [14**]. The benefits of improved glucose metabolism through consumption of barley kernel-based bread display substantial inter-individual variability with responders having a gut microbiota enriched in *Prevotella copri* that may be contributing by potentially promoting glucose storage [52]. The effects of eating traditionally prepared artisanal sourdough bread (coveted for its health benefits) compared to industrially made white bread, were found to be highly personal to each type of bread [49]. Interestingly, machine-learning algorithms predicted the type of bread inducing a lower glycemic response in each person based on gut microbiome compositional data [49].

In a further display of inter individual variation through gut microbiome involvement, dysbiosis resulting by the intake of non-caloric artificial sweeteners (NAS) can lead to induction of glucose intolerance. The response of the individuals to the consumption of NAS is highly variable and gut microbial composition related [53^{*}]. At a time of obesity reaching pandemic proportions and diet interventions to reduce weight are on the rise but generally fail in the long run, in another recent study we showed that the microbiome is implicated in what is termed the ‘yo-yo’ effect, defined as accumulation of excessive weight gain when undergoing weight gain-and-loss cycles [54^{*}]. It was found that the microbiome of normal weight mice with a history of obesity have a microbiome composition different to that of normal mice (without part obesity), that drives the ‘yo-yo’ effect. Furthermore, transferring the microbiome of ex-obese mice to germ free (GF) normal weight mice results in excessive weight gain and other unfavorable metabolic syndrome effects when given a high fat diet (HFD). The weight gain of the mice was predicted with high accuracy using only microbial taxa abundances and the top ranked bacteria in predicting weight gain are bacteria capable of breaking flavanoids and Lactobacillus. Furthermore, the mechanism underlying the yo-yo effect is that the energy expenditure of ex-obese mice is lower compared to normal mice when both are fed a HFD, and when supplementing ex-obese mice with Apigenin or Naringenin (plant derived substances belonging to the Flavanoid family), the energy expenditure increases and the ‘yo-yo’ effect is gone [54^{*}]. Another study discovered a positive feedback loop between gut microbiota and the central nervous system, that promotes hyperphagia and increased energy storage as fat [55]. It was shown that acetate production increases due to a gut microbiota–nutrient interaction in HFD-fed rodents, which in-turn results in parasympathetic nervous system activation and increased ghrelin (the hormone which regulates appetite) and glucose stimulated insulin secretion. Collectively, these studies demonstrate the capacity of massive quantification of person-specific data in contributing to a heightened capability to utilize computational platforms in predicting clinical outcomes.

Conclusion

As in the emerging field of personalized medicine, there are increasing efforts to go beyond the one-fit-for-all diet approaches [3]. Driven by technological advances, our insights into human variation (with all that it encompasses) and its effect on disease risk are steadily increasing. Our inherited genome and our microbial ‘second genome’ both intricately modulate our response to diet; this has been studied and established. There is now a need for developing new tools that will allow using the whole potential of individual microbiome and genetic fingerprints for the benefit of PN. This is no easy feat and requires new approaches in analysis of the ever expanding data being accumulated. The instruments from the

emerging field of machine learning and big data were successfully implemented in a series of studies [49,54^{*},55,56,57], and with more data available the proper utilization of information will become a crucial point (Figure 1). Public acceptance of genetic testing and microbiome characterization towards implementing PN in disease prevention is a predominant factor along with user participation and involvement, as well as their nutrient environment that all play an important role since diet compliance is crucial [58]. Moreover, the long term efficacy of PN and its advantages over customary population based dietary recommendations in preventing, ameliorating and treating metabolic syndrome-associated disorders remain to be determined. Of note, smartphones are becoming a universal accessory with the number of smartphone users estimated to reach 2.5 billion by 2018 (Statistica; URL: <https://www.statista.com/statistics/330695/number-of-smartphone-users-worldwide/>) and can be utilized as a tool in the implementation of PN regimens through the use of interactive diet related applications for monitoring nutrient consumption (Figure 1) [59,60]. These can aid in improving long-term compliance, considered by many in the field to co-constitute the biggest hurdle in integrating ‘healthier’ dietary habits in large populations. Another important challenge, as a more refined understanding of how variability influences disease risk is achieved, relates to ethical issues concerning the safeguarding of delicate individual-specific information as well as who can access this data and for what reason. With these limitations and challenges notwithstanding, integrating ‘big data’ including genomic and microbiome data into personalized nutrition and personalized medicine constitutes one of the most exciting and promising approaches in tackling common human metabolic disorders.

Conflict of interest statement

Eran Elinav & Eran Segal are paid consultants to Daytwo.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
 - of outstanding interest
1. Cani PD, Everard A: **Talking microbes: when gut bacteria interact with diet and host organs.** *Mol Nutr Food Res* 2016, **60**:58-66.
 2. Franks PW, McCarthy MI: **Exposing the exposures responsible for type 2 diabetes and obesity.** *Science* 2016, **354**:69-73.
 3. Magni P, Bier DM, Pecorelli S, Agostoni C, Astrup A, Brighenti F, Cook R, Folco E, Fontana L, Gibson RA et al.: **Perspective: improving nutritional guidelines for sustainable health policies: current status and perspectives.** *Adv Nutr* 2017, **8**:532-545.
 4. Stevens J, Oakkar EE, Cui Z, Cai J, Truesdale KP: **US adults recommended for weight reduction by 1998 and 2013 obesity**

- guidelines, NHANES 2007-2012. *Obesity (Silver Spring)* 2015, **23**:527-531.
5. NCD Risk Factor Collaboration (NCD-RisC): **Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants.** *Lancet (London, England)* 2016, **387**:1513-1530.
 6. Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D, Uhl-Hochgraeber K: **Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.** *BMC Public Health* 2010, **10**:529.
 7. Greenwood DC, Threapleton DE, Evans CEL, Cleghorn CL, Nykjaer C, Woodhead C, Burley VJ: **Glycemic index, glycemic load, carbohydrates, and type 2 diabetes: systematic review and dose-response meta-analysis of prospective studies.** *Diabetes Care* 2013, **36**:4166-4171.
 8. American Diabetes Association: **4. Prevention or delay of type 2 diabetes.** *Diabetes Care* 2016, **39**(Suppl 1):S36-S38.
 9. Gallwitz B: **Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.** *Diabetes Care* 2009, **32**(Suppl 2):S322-S325.
 10. Böhm A, Weigert C, Staiger H, Häring H-U: **Exercise and diabetes: relevance and causes for response variability.** *Endocrine* 2016, **51**:390-401.
 11. Winett RA, Davy BM, Savla J, Marinik EL, Winett SG, Baugh ME, Flack KD: **Using response variation to develop more effective, personalized behavioral medicine? Evidence from the Resist Diabetes study.** *Transl Behav Med* 2014, **4**:333-338.
 12. Heianza Y, Qi L: **Gene-diet interaction and precision nutrition in obesity.** *Int J Mol Sci* 2017, **18**:787.
 13. Park JH, Yoo Y, Park YJ: **Epigenetics: linking nutrition to molecular mechanisms in aging.** *Prev Nutr food Sci* 2017, **22**:81-89.
 14. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M *et al.*: **Personalized nutrition by prediction of glycemic responses.** *Cell* 2015, **163**:1079-1094.
- Authors developed a revolutionary algorithm for predicting postprandial glucose responses by integrating microbiome composition, blood tests and anthropometrics of 1000 people. This is the first study that utilizes a machine learning approach and microbiome information for personally tailored diet intervention.
15. Mozaffarian D: **Dietary and policy priorities for cardiovascular disease, diabetes, and obesity.** *Circulation* 2016, **133**:187-225.
 16. Claus SP, Guillou H, Ellero-Simatos S: **The gut microbiota: a major player in the toxicity of environmental pollutants?** *NPJ Biofilms Microbiomes* 2016, **2**:16003.
 17. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W *et al.*: **Initial sequencing and analysis of the human genome.** *Nature* 2001, **409**:860-921.
 18. International HapMap Consortium KA, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P *et al.*: **A second generation human haplotype map of over 3.1 million SNPs.** *Nature* 2007, **449**:851-861.
 19. Burn J, Watson M: **The human variome project.** *Hum Mutat* 2016, **37**:505-507.
 20. 1000 Genomes Project Consortium A, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA *et al.*: **A global reference for human genetic variation.** *Nature* 2015, **526**:68-74.
 21. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, Klemm A, Flicek P, Manolio T, Hindorf L *et al.*: **The NHGRI GWAS catalog, a curated resource of SNP-trait associations.** *Nucleic Acids Res* 2014, **42**:D1001-D1006.
 22. Timson DJ: **The molecular basis of galactosemia — past, present and future.** *Gene* 2016, **589**:133-141.
 23. Kakkoura MG, Loizidou MA, Demetriou CA, Loucaides G, Daniel M, Kyriacou K, Hadjisavvas A: **The synergistic effect between the Mediterranean diet and GSTP1 or NAT2 SNPs decreases breast cancer risk in Greek-Cypriot women.** *Eur J Nutr* 2017, **56**:545-555.
 24. Corella D, Peloso G, Arnett DK, Demissie S, Cupples LA, Tucker K, Lai C-Q, Parnell LD, Coltell O, Lee Y-C *et al.*: **APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations.** *Arch Intern Med* 2009, **169**:1897-1906.
 25. Corella D, Carrasco P, Sorlí JV, Estruch R, Rico-Sanz J, Martínez-González MA, Salas-Salvado J, Covas MI, Coltell O, Arós F *et al.*: **Mediterranean diet reduces the adverse effect of the TCF7L2-rs7903146 polymorphism on cardiovascular risk factors and stroke incidence: a randomized controlled trial in a high-cardiovascular-risk population.** *Diabetes Care* 2013, **36**:3803-3811.
 26. Pavlidis C, Lanara Z, Balasopoulou A, Nebel J-C, Katsila T, Patrinos GP: **Meta-analysis of genes in commercially available nutrigenomic tests denotes lack of association with dietary intake and nutrient-related pathologies.** *OMICS* 2015, **19**:512-520.
- The authors addressed the issue of consistency in scientific studies reporting nutrigenomics data by conducting a meta-analysis studying gene-diet interaction for 38 genes included in commercially available nutrigenomics tests and found that there was no significant association for these genes.
27. Li SX, Imamura F, Ye Z, Schulze MB, Zheng J, Ardanaz E, Arriola L, Boeing H, Dow C, Fagherazzi G *et al.*: **Interaction between genes and macronutrient intake on the risk of developing type 2 diabetes: systematic review and findings from European Prospective Investigation into Cancer (EPIC)-InterAct.** *Am J Clin Nutr* 2017, **106**:263-275.
- The reported contribution of gene-macronutrient interactions in the development of type 2 diabetes was addressed in this study. A large scale meta-analysis was carried out to ascertain whether eight gene-macronutrient interactions identified in the literature as risk factors for type 2 diabetes were replicated in the large scale EPIC (European Prospective Investigation into Cancer)-InterAct case-cohort. These interactions were not replicated highlighting the need for independent replication of reported interactions in nutrigenomics studies.
28. Sender R, Fuchs S, Milo R: **Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans.** *Cell* 2016, **164**:337-340.
 29. Zhao L: **Genomics: the tale of our other genome.** *Nature* 2010, **465**:879-880.
 30. Norman JM, Handley SA, Baldrige MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P *et al.*: **Disease-specific alterations in the enteric virome in inflammatory bowel disease.** *Cell* 2015, **160**:447-460.
 31. van de Pol JAA, van Best N, Mbakwa CA, Thijs C, Savelkoul PH, Arts ICW, Hornef MW, Mommers M, Penders J: **Gut colonization by methanogenic archaea is associated with organic dairy consumption in children.** *Front Microbiol* 2017, **8**:355.
 32. Underhill DM, Iliev ID: **The mycobiota: interactions between commensal fungi and the host immune system.** *Nat Rev Immunol* 2014, **14**:405-416.
 33. McSorley HJ, Hewitson JP, Maizels RM: **Immunomodulation by helminth parasites: defining mechanisms and mediators.** *Int J Parasitol* 2013, **43**:301-310.
 34. Sartor RB, Wu GD: **Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches.** *Gastroenterology* 2017, **152**:327-339.e4.
 35. Grice EA, Segre JA: **The human microbiome: our second genome.** *Annu Rev Genomics Hum Genet* 2012, **13**:151-170.
 36. Structure, function and diversity of the healthy human, microbiome. *Nature* 2012, **486**:207-214.
 37. Ding T, Schloss PD: **Dynamics and associations of microbial community types across the human body.** *Nature* 2014, **509**:357-360.

38. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP *et al.*: **A core gut microbiome in obese and lean twins.** *Nature* 2009, **457**:480-484.
39. Zhu A, Sunagawa S, Mende DR, Bork P: **Inter-individual differences in the gene content of human gut bacterial species.** *Genome Biol* 2015, **16**:82.
40. Bach Knudsen KE: **Microbial degradation of whole-grain complex carbohydrates and impact on short-chain fatty acids and health.** *Adv Nutr* 2015, **6**:206-213.
41. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL: **Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.** *N Engl J Med* 2013, **368**:1575-1584.
42. Cho CE, Taesuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, Sutter JL, Caudill MA: **Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial.** *Mol Nutr Food Res* 2017, **61**:1600324.
43. Cassidy A, Minihane A-M: **The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids.** *Am J Clin Nutr* 2017, **105**:10-22.
44. Tomás-Navarro M, Vallejo F, Sentandreu E, Navarro JL, Tomás-Barberán FA: **Volunteer stratification is more relevant than technological treatment in orange juice flavanone bioavailability.** *J Agric Food Chem* 2014, **62**:24-27.
45. Meyer KA, Bennett BJ: **Diet and gut microbial function in metabolic and cardiovascular disease risk.** *Curr Diab Rep* 2016, **16**:93.
46. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA *et al.*: **Diet rapidly and reproducibly alters the human gut microbiome.** *Nature* 2014, **505**:559-563.
47. Faith JJ, McNulty NP, Rey FE, Gordon JL: **Predicting a human gut microbiota's response to diet in gnotobiotic mice.** *Science* 2011, **333**:101-104.
48. Korem T, Zeevi D, Zmora N, Weissbrod O, Bar N, Lotan-Pompan M, Avnit-Sagi T, Kosower N, Malka G, Rein M *et al.*: **Bread affects clinical parameters and induces gut microbiome-associated personal glycemic responses.** *Cell Metab* 2017, **25**:1243-1253.e5.
- Traditional sourdough bread is considered superior to industrial made white bread in terms of health benefits. However, effects of eating each type of bread were found to be variable among individuals and were dependent on microbiome composition. Furthermore, machine-learning algorithms were implemented and predicted the type of bread inducing a lower glycemic response in each individual based on their microbiome composition.
49. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R *et al.*: **Linking long-term dietary patterns with gut microbial enterotypes.** *Science* 2011, **334**:105-108.
50. Levy M, Thaiss CA, Zeevi D, Dohnalová L, Zilberman-Schapira G, Mahdi JA, David E, Savidor A, Korem T, Herzog Y *et al.*: **Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling.** *Cell* 2015, **163**:1428-1443.
51. Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Hallen A, Martens E, Björck I, Bäckhed F: **Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella.** *Cell Metab* 2015, **22**:971-982.
52. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A *et al.*: **Artificial sweeteners induce glucose intolerance by altering the gut microbiota.** *Nature* 2014, **514**:181-186.
53. Thaiss CA, Itav S, Rothschild D, Meijer M, Levy M, Moresi C, Dohnalová L, Braverman S, Rozin S, Malitsky S *et al.*: **Persistent microbiome alterations modulate the rate of post-dieting weight regain.** *Nature* 2016 <http://dx.doi.org/10.1038/nature20796>.
- Using germ free mice authors demonstrate the underlining mechanism of the "yo-yo effect". This study finds that Apigenin or Naringenin increase energy expenditure in ex-obese mice fed a HFD and shows the causal role of the microbiome by changing Apigenin or Naringenin gut levels.
54. Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, Petersen KF, Kibbey RG, Goodman AL, Shulman GI: **Acetate mediates a microbiome-brain- β -cell axis to promote metabolic syndrome.** *Nature* 2016, **534**:213-217.
- Authors discover how the diet-microbiota interaction can drive obesity and metabolic syndrome. The study uses high fat fed mice to demonstrate that increased production of acetate by microbiome leads to activation of the parasympathetic nervous system which results in elevated ghrelin secretion and glucose-stimulated insulin secretion.
55. Albers DJ, Levine M, Gluckman B, Ginsberg H, Hripcsak G, Mamykina L: **Personalized glucose forecasting for type 2 diabetes using data assimilation.** *PLoS Comput Biol* 2017, **13**:e1005232.
56. Sudharsan B, Peeples M, Shomali M: **Hypoglycemia prediction using machine learning models for patients with type 2 diabetes.** *J Diabetes Sci Technol* 2015, **9**:86-90.
57. Fallaize R, Mcready AL, Butler LT, Ellis JA, Lovegrove JA: **An insight into the public acceptance of nutrigenomic-based personalised nutrition.** *Nutr Res Rev* 2013, **26**:39-48.
58. Celis-Morales C, Livingstone KM, Marsaux CF, Mcready AL, Fallaize R, O'Donovan CB, Woolhead C, Forster H, Walsh MC, Navas-Carretero S *et al.*: **Effect of personalized nutrition on health-related behaviour change: evidence from the Food4Me European randomized controlled trial.** *Int J Epidemiol* 2017, **46**:578-588.
59. Ashman AM, Collins CE, Brown LJ, Rae KM, Rollo ME: **Validation of a smartphone image-based dietary assessment method for pregnant women.** *Nutrients* 2017, **9**:73.
60. Borgen I, Garnweidner-Holme LM, Jacobsen AF, Bjerkan K, Fayyad S, Joranger P, Lilleengen AM, Mosdøl A, Noll J, Småstuen MC *et al.*: **Smartphone application for women with gestational diabetes mellitus: a study protocol for a multicentre randomised controlled trial.** *BMJ Open* 2017, **7**:e013117.